- Home
- CHN vs BDSX Comparison
CHN vs BDSX Comparison
Compare CHN & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHN
- BDSX
- Stock Information
- Founded
- CHN 1992
- BDSX 2005
- Country
- CHN United States
- BDSX United States
- Employees
- CHN N/A
- BDSX N/A
- Industry
- CHN Investment Managers
- BDSX Precision Instruments
- Sector
- CHN Finance
- BDSX Health Care
- Exchange
- CHN Nasdaq
- BDSX Nasdaq
- Market Cap
- CHN 128.4M
- BDSX 115.4M
- IPO Year
- CHN N/A
- BDSX 2020
- Fundamental
- Price
- CHN $11.51
- BDSX $0.55
- Analyst Decision
- CHN
- BDSX Strong Buy
- Analyst Count
- CHN 0
- BDSX 3
- Target Price
- CHN N/A
- BDSX $2.93
- AVG Volume (30 Days)
- CHN 31.8K
- BDSX 341.6K
- Earning Date
- CHN 01-01-0001
- BDSX 05-07-2025
- Dividend Yield
- CHN 0.19%
- BDSX N/A
- EPS Growth
- CHN N/A
- BDSX N/A
- EPS
- CHN N/A
- BDSX N/A
- Revenue
- CHN N/A
- BDSX $71,323,000.00
- Revenue This Year
- CHN N/A
- BDSX $32.90
- Revenue Next Year
- CHN N/A
- BDSX $24.65
- P/E Ratio
- CHN N/A
- BDSX N/A
- Revenue Growth
- CHN N/A
- BDSX 45.30
- 52 Week Low
- CHN $9.00
- BDSX $0.51
- 52 Week High
- CHN $12.98
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- CHN 38.88
- BDSX 35.73
- Support Level
- CHN $11.40
- BDSX $0.53
- Resistance Level
- CHN $11.95
- BDSX $0.65
- Average True Range (ATR)
- CHN 0.35
- BDSX 0.07
- MACD
- CHN -0.05
- BDSX 0.00
- Stochastic Oscillator
- CHN 39.91
- BDSX 15.97
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.